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Abstract The time to first antibiotic dose (TFAD) has been
mentioned as an important performance indicator in
community-acquired pneumonia (CAP). However, the
advice to minimise TFAD to 4 hours (4 h) is only based
on database studies. We prospectively studied the effect of
minimising the TFAD on the early clinical outcome of
moderate–severe CAP. On admission, patients’ medical
data and TFAD were recorded. Early clinical failure was
expressed as the proportion of patients with clinical
instability, admission to the intensive care unit (ICU) or
mortality on day three. Of 166 patients included in the
study, 27 patients (29.7%) with TFAD <4 h had early
clinical failure compared to 23 patients (37.7%) with TFAD
>4 h (odds ratio [OR] 0.69; 95% confidence interval [CI]
0.35–1.35). In multivariate analysis, the pneumonia severity
index (OR 1.03; 95%CI 1.01–1.04), confusion (OR 2.63;
95%CI 1.14–6.06), Staphylococcus aureus infection (OR
7.26; 95%CI 1.33–39.69) and multilobar pneumonia (OR
2.40; 95%CI 1.11–5.22) but not TFAD were independently
associated with early clinical failure. Clinical parameters on
admission other than the TFAD predict early clinical
outcome in moderate–severe CAP. In contrast to severe
CAP necessitating treatment in the ICU directly, in the case
of suspected moderate–s e v e r eC A P ,t h e r ei st i m et o
establish a reliable diagnosis of CAP before antibiotics are
administered. Therefore, the implementation of the TFAD
as a performance indicator is not desirable.
Introduction
Quality of care measurements and performance indicators
are increasingly important in medical practice, in parti-
cular, in the treatment of high prevalence diseases [1].
Community-acquired pneumonia (CAP) is one of the
leading causes of hospitalisation and mortality in the
western world and is associated with high healthcare costs
[2]. Therefore, performance indicators play an important
role in the development of pneumonia care standards.
Current guidelines advise to minimise the time to first
antibiotic dose (TFAD) in patients suspected of pneumonia.
Moreover, the TFAD has frequently been mentioned as an
important performance indicator in patients admitted
because of pneumonia [3]. The European guidelines’
recommendation is to initiate antibiotics within the first
two hours of hospitalisation, whereas the current Infectious
Disease Society of America/American Thoracic Society
consensus guidelines advise the first antibiotic dose to be
administered while the patient is still in the emergency
department [4, 5]. These recommendations are mainly
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an association between antibiotic timing and severity-
adjusted outcome in pneumonia [6, 7]. Therefore, as the
advice to minimise the TFAD is only based on grade C
level of evidence and more recent studies do not support
their findings, the validity of these studies has been
questioned [4, 8–12]. Additionally, minimising the TFAD
is associated with drawbacks as well. Adopting the TFAD
as a performance indicator may lead to the prioritisation of
pneumonia patients over others and unnecessary antibiotic
treatment for patients who ultimately receive another
diagnosis (e.g. congestive heart failure), contributing to an
increase in antibiotic use, side-effects, resistance and costs.
Another concern is that patients may receive inappropriate
antibiotics for suspected pneumonia due to time pressure
[13, 14]. This is illustrated by a recent study which shows
that linking TFAD within four hours (4 h) to financial
compensation may result in less optimal care [15].
Preferably, performance indicators are based on recom-
mendations with adequate scientific proof of their effec-
tiveness, safety and efficiency [16]. The need for evidence
is even more urgent in view of today’s trend to use
performance indicators as the basis for public reporting and
plans to implement quality measures such as the TFAD
in pay-for-performance programmes [17]. When adopting
the TFAD as a quality measure in pay-for-performance
programmes for the treatment of CAP, more studies on the
impact of the TFAD on outcome are needed. Therefore, we
prospectively studied the effect of the TFAD on early
clinical outcome in patients hospitalised with moderate–
severe CAP admitted to general medical and pulmonary
wards.
Methods
Patients and setting
The prospective cohort of patients in this study was derived
from a multicentre prospective randomised controlled trial
on the cost-effectiveness of an early switch from parenteral
to oral therapy for severe CAP [18]. Patients were included
during a three-year period from July 2000 to June 2003 in
University Medical Centres and their affiliated teaching
hospitals in the Netherlands. All adult patients (age 18 years
and above) admitted to the hospital because of CAP were
eligible for inclusion. CAP was defined as at least two
symptoms of acute lower respiratory tract infection with
onset before admission and a new or progressive pulmonary
infiltrate on a chest radiograph. Written and oral informed
consent was retrieved from all of the patients included.
Moderate–severe pneumonia was defined as a pneumonia
severity index score >90 and necessitating admission to the
general medical or pulmonary ward, without immediate
treatment in the intensive care unit (ICU) [19, 20].
Antibiotic treatment was based on the Dutch guidelines
for pneumonia management [21].
Data collection and definitions
For the current study, patients were included at the time of
hospital admission and were followed for at least three days
after diagnosis. On admission, data were collected on
demographics, comorbidity, antibiotic use prior to admis-
sion, duration of symptoms before admission, pneumonia
severity scores, the TFAD, site of administration of first
antibiotic dose and initial choice of antibiotics [20, 22]. In
addition, cultures, serology and urinary antigen tests were
performed to establish an aetiological diagnosis. During
follow-up, in-hospital clinical data were recorded. On the
third day of admission, patients were evaluated for clinical
outcome by means of clinical failure, including clinical in-
stability, mortality and admission to the ICU. Clinical
instability was defined as: respiratory rate >25/min, periph-
eral oxygen saturation <90%, partial pressure of arterial
oxygen <60 mmHg, haemodynamic instability or altered
mental status [23]. Indication for ICU admission was the
need for mechanical ventilation or vasopressors, as deter-
mined by the treating physician [4, 5].
Microbiological evaluation
Details of the microbiological procedures have been
described earlier [18]. In short, sputum and blood samples
were collected, cultured and evaluated according to standard
procedures. Urinary antigen tests (Binax Inc., Portland, ME)
were used to detect antigens of Legionella pneumophila and
Streptococcus pneumoniae. Acute and convalescent sera
were collected and tested for Mycoplasma pneumoniae,
L. pneumophila and Chlamydia pneumoniae. Pathogenic
micro-organisms cultured from blood or sputum detected by
urinary antigen test or a seroconversion were considered to
be the cause of the episode of pneumonia.
Definitions of antibiotic treatment
The TFAD is defined as the time elapsed between
presentation to the emergency department and first antibi-
otic administration, as recorded on the drug accountability
lists kept by the nursing staff. The ward to needle time was
defined as the time elapsed between admission to the ward
and the first antibiotic administration. Appropriate empiric
antibiotic treatment was defined as all identified pathogens
being susceptible for the antibiotics administered. In case
no aetiology was determined, empiric antibiotic treatment
was also considered as appropriate.
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Patients with antibiotic treatment prior to hospital admission
were excluded from the analysis. To explore potential
confounders, the baseline characteristics of patients who
received antibiotics within four hours (<4 h) after admission
tothehospitalwerecomparedtothoseofpatientswiththefirst
antibiotic dose after four hours of admission (>4 h). A
variation of >10% in baseline characteristics was estimated to
be relevant. The objective of the study was to evaluate the
influence of the TFAD on early clinical outcome. Early
clinical failure was defined as clinical instability, admission to
the ICU or mortality on day three of hospitalisation. Patients
with TFAD <4 h were compared to patients with TFAD >4 h
for differences in the rate of early clinical failure. In addition,
the time–effect relation in the TFAD and early clinical failure
was explored. Finally, multivariable assessment of clinical
parameters on admission predictive of clinical failure on day
three of admission was performed [23].
Statistical methods
For comparisons between subgroups of patients with
continuous scaled data, we used Student’s t-test and for
skewed scaled data, the Mann-Whitney U-test was used.
Categorical variables were compared using the chi-square
test and by estimation of the odds ratio (OR) with
corresponding 95% confidence intervals (CI) for the selected
patients. The ideal TFAD was assessed by using stepwise
cut-off point’s at 1-h intervals up to 8 h after admission.
Spearman’s correlation was used to estimate a time–effect
relationship between the TFAD and clinical failure. Multi-
variate logistic regression modelling was used and significant
interactions were included in the model with a P-value<0.10
as the threshold. Forward selection was performed to verify
whether any previously deleted potentially relevant charac-
teristic had been eliminated incorrectly from the model.
All analytical procedures were performed using SPSS v15.0
for Windows (SPSS Inc., Chicago, IL).
Results
Baseline characteristics of the study population
Of 200 patients admitted with moderate–severe CAP to one
of the participating hospitals, the TFAD could be assessed
appropriately. Thirty-four (17%) patients had received
antibiotic treatment prior to hospitalisation and were
consequently excluded for further analysis, leaving 166
patients for analysis. In 152 (91.6%) patients, follow-up
until the third day of admission was accomplished (Fig. 1).
Ninety-five (57.2%) patients presented to the emergency
department of the University Medical Center Utrecht, the
Netherlands, and 71 (42.8%) to one of its affiliated regional
teaching hospitals. Patients admitted to one of the teaching
hospitals received more often their first antibiotic dose in
the emergency room and slightly more severely ill patients
were admitted to the University Medical Center; however,
this was not statistically significant. The mean pneumonia
severity index score in the study population was 108.8
(±24.1 standard deviation [SD]) and the mean age was
67.2 years (±14.5 SD). One hundred and seven (64.5%)
patients had at least one co-morbid illness, such as
congestive heart failure, neoplasm, cerebrovascular disease,
chronic renal failure or chronic obstructive pulmonary
disease. The aetiology could be determined in 79 (47.6%)
patients. S. pneumoniae was the most frequently identified
pathogen (38 [22.9%] patients). Beta-lactam monotherapy
was the most frequently instituted initial antibiotic therapy
in 131 (79.4%) patients and 30 (18.2%) patients received
combination therapy with beta-lactam and macrolide
antibiotics. In 152 (91.6%) patients, empiric antibiotic
treatment was appropriate, of which 91 (59.9%) patients
received appropriate antibiotics within 4 h (Table 1).
TFAD and the ‘4 hour rule’
Overall, the median TFAD was 3 h 12 min. In 100 patients
(60.2%), the TFAD was <4 h (median 2 h 23 min; range 0 h
25 min to 3 h 46 min) and in 66 (39.8%) patients it was
>4 h (median 5 h 17 min; range 4 h 00 min to 73 h 15 min).
The ward to needle time was 0 h 30 min (±0 h 52 min SD)
in patients with first antibiotic dose <4 h and 1 h 27 min
(±8 h 19 min SD) in patients with delayed antibiotic
administration (P<0.01). No important differences in
patients’ characteristics, pneumonia severity scores, clinical
signs, symptoms or causative pathogens were observed
between both groups (Table 1). Importantly, no relevant
difference in the duration of symptoms before hospital
admission or appropriateness of the initiated antibiotics in
patients with or without TFAD <4 h could be identified.
However, a baseline difference in the prevalence of
cerebrovascular disease and chronic obstructive pulmonary
200 patients 
moderate- severe 
community-acquired pneumonia
166 patients
included in analysis
152 patients
completed study protocol 
14 patients (7.0%)
lost to follow-up
34 patients (17.0%)
antibiotic use prior 
to hospitalisation
Fig. 1 Flowchart of patients included in the study
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obstructive pulmonary disease as a co-morbid illness had
significantly more often early antibiotic administration
(43.0% versus 27.3%), whereas patients with cerebrovas-
cular disease had more often delayed administration of first
antibiotic dose (13.6% versus 3.0%).
The effect of the TFAD on early clinical outcome
Of the 152 patients followed until day three of hospital-
isation, the TFAD was <4 h in 91 (59.9%) patients and >4 h
in 61 (40.1%) patients. Twenty-four patients (26.4%) with
early antibiotic administration had clinical instability on
day three, as compared to 22 (36.1%) patients with TFAD
>4 h. This was not statistically significant (OR 0.65; 95%
CI 0.32–1.31; P=0.22). There was also no significant
difference in the rates of early clinical failure for patients
with TFAD <4 h and patients with TFAD >4 h (OR 0.69;
95% CI 0.35–1.35; P=0.28) (Table 2). Figure 2 shows the
influence of minimising the TFAD on early clinical
outcome evaluated by stepwisely increasing the TFAD with
1-h intervals up to 8 h after admission. Rates for early
clinical failure did not increase substantially by increasing
the TFAD stepwisely up to 8 h. Furthermore, no time–effect
relation was observed between the TFAD and early clinical
failure (Spearman’s correlation 0.12, P=0.13) (Fig. 2).
Factors predictive of early clinical failure
In the univariate and multivariate analysis, we explored
parameters on admission predictive for early clinical failure
in severe CAP. The TFAD was not independently associ-
ated with early clinical failure. However, the pneumonia
severity index score on admission (OR 1.03; 95% CI 1.01–
1.04), confusion on admission (OR 2.63; 95% CI 1.14–
6.06), S. aureus infection (OR 7.26; 95% CI 1.33–39.69)
and multilobar pneumonia (OR 2.40; 95% CI 1.11–5.22)
were independently predictive for a less favourable clinical
outcome on day three of hospitalisation (P≤0.03) (Table 3).
As mentioned before, patients with chronic obstructive
pulmonary disease as a co-morbidity had more often earlier
antibiotic administrated, while patients with cerebrovascu-
lar disease had more often delayed antibiotic administration
(Table 1). Nevertheless, co-morbidity as chronic obstructive
pulmonary disease and cerebrovascular disease are not
independently associated with early clinical failure and,
therefore, are ruled out as potential confounders (Table 3).
Discussion
We demonstrated that TFAD within four hours was not
predictive for early clinical failure in moderate–severe CAP.
Table 1 Baseline characteristics stratified by time to first antibiotic
dose (TFAD) < 4 h of admission to the hospital*
Antibiotics
<4h, n=100
(60.2%)
Antibiotics
>4h, n=66
(39.8%)
Patient characteristics
Mean age (years) ± SD 66.7±14.1 68.1±15.1
Female 37 (37.0) 21 (31.8)
Mean pneumonia severity
index score ± SD
108.0±21.0 110.1±28.1
Curb-65 score ≥ 3 33 (33.0) 20 (30.3)
Comorbidity
A least one co-morbid illness 65 (65.0) 42 (63.6)
Congestive heart failure 14 (14.0) 4 (6.1)
Neoplasm 23 (23.0) 14 (21.2)
Cerebrovascular disease 3 (3.0) 9 (13.6)
Chronic renal disease 8 (8.0) 7 (10.6)
Chronic obstructive
pulmonary disease
42 (42.0) 18 (27.3)
Clinical signs or symptoms
Median days of symptoms
prior to visiting ER ± SD
3.3±3.6 3.0±4.9
Mean temperature, °C 38.6±1.3 38.5±1.2
Mean pulse/min 106.8±23.6 107.7±22.2
Mean systolic
blood pressure/mmHg
136.5±26.0 133.5±26.3
Mean respiration rate/min 26.8±9.3 26.9±9.2
Mean arterial pH 7.45±0.7 7.45±0.5
Mean arterial pO2/mmHg 66.9±19.2 64.3±17.9
Confusion 25 (25.0) 18 (27.3)
Site of admission
University Medical Center 58 (58.0) 37 (56.1)
Teaching hospital 42 (42.0) 29 (43.9)
Initiated antibiotics
Median TFAD (h) ± SD 2:23±0:54 5:17±13.3
Median ward to needle
time ± SD
0:30±0:52 1:27±8:19
Appropriate empiric
antibiotic treatment
91 (91.0) 61 (92.4)
Beta-lactam antibiotics 65 (75.8) 56 (84.8)
Beta-lactam and macrolide
antibiotics
20 (20.2) 10 (15.2)
Microbiological evaluation
Aetiology determined
a 51 (51.0) 28 (42.4)
Streptococcus pneumoniae 25 (25.0) 13 (19.7)
Staphylococcus aureus 5 (5.0) 3 (4.5)
Haemophilus influenzae 4 (4.0) 2 (3.0)
Legionella pneumophila 6 (6.0) 1 (1.5)
Chlamydia pneumoniae 4 (4.0) 2 (3.0)
Mycoplasma pneumoniae 2 (2.0) 2 (3.0)
Other pathogens
b 9 (9.0) 7 (10.6)
*Data are percentages (absolute numbers) unless otherwise specified
aIn six (3.5%) patients, multiple pathogens were identified
bOther pathogens include: gram-negative enteric species (n=9; 5.4%);
Pseudomonas aeruginosa (n=1; 0.6%); Klebsiella pneumonia (n=1;
0.6%); Moraxella catarrhalis (n=4; 2.4%)
916 Eur J Clin Microbiol Infect Dis (2009) 28:913–919Additionally, the effect of postponing the administration of
antibiotics up to 8 h after admission was not associated with
an effect on the early clinical outcome. Furthermore, no
time–effect relation was observed between the TFAD and
early clinical failure.
Therefore, this report suggests that earlier antibiotic
administration has no demonstrable beneficial effect on the
early achievement of clinical stability or cure in patients
admitted with moderate–severe CAP admitted to general
medical or pulmonary wards.
Our study differs from previous studies in several
important aspects. The strengths of this study were the
prospective data collection in a multicentre setting and the
strict patient selection; only patients with moderate-severe
CAP primarily treated in general wards were included. Two
large retrospective database studies reported the TFAD as
an important predictor for mortality in patients with CAP.
Meehan et al. demonstrated that antibiotic delivery time
less than 8 h was associated with a 15% lower odds of
30-day mortality (95% CI 075–0.96) [6]. In addition,
Houck et al. described that antibiotic treatment within 4 h
was associated with decreased mortality and length of
hospital stay [7]. These results have led to the implemen-
tation of minimising the TFAD as a recommendation in
guidelines on CAP. Yet, the major weakness of these
studies was the retrospective study design. Moreover,
correction for pre-hospital parameters such as antibiotic
use and duration of symptoms before hospital admission
was not performed, so heterogeneity in the study population
could have led to a confounding effect [10]. Likewise,
Battleman et al. examined the TFAD in patients hospital-
ised with pneumonia and concluded that timely antibiotic
administration was associated with a shorter length of
hospital stay [24], while several other studies could not
identify early antibiotic administration as an independent
predictor for diminished mortality [9, 10, 12, 15, 25–27].
The influence of timely antibiotic administration on early
clinical failure has been studied twice before [10, 11]. The
findings of these reports are in agreement with our results:
the TFAD does not influence the rate of clinical failure. In
contrast to our study, these studies included patients with
mild CAP as well. However, in a heterogeneous study
population of patients with mild to severe pneumonia, the
effect of minimising the TFAD on clinical stability may be
underestimated, since patients with more severe pneumonia
often receive priority in treatment in the emergency room [6,
10]. For purpose of the current study, we excluded patients
with severe CAP directly admitted to the ICU, minimising
the potential confounding effect of early antibiotic adminis-
tration in the most critically ill patients. Moreover, the debate
on minimising the TFAD with associated drawbacks is
particularly applicable to large groups of patients admitted
with moderate–severe CAP to general wards instead of the
few admitted to the ICU directly.
In addition, the timing of antibiotic administration is influ-
enced by the difficulty of diagnosis. In line with other studies,
patients in our cohort with cerebrovascular disease often
receive their antibiotics later, whereas patients with chronic
obstructive pulmonary disease receive antibiotics earlier [12].
This can be partly explained by the difficulty in diagnosing a
respiratory tract infection in the first patient group.
These issues raised illustrate the complexity in studying
the predictive value of the TFAD on outcome in patients
hospitalised with CAP. Efforts to promote the early
administration of appropriate antibiotics in patients hospi-
talised with CAP make good clinical sense. However, our
results and previous studies emphasise the difficulty in
demonstrating the attributable impact of these procedures
on clinical outcome. It may be inappropriate to expect
hospitals to deliver antibiotics to all patients suspected of
pneumonia within four hours of presentation. This approach
Time to first antibiotic dose (hours)
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Fig. 2 The effect of the time to first antibiotic dose (TFAD) on the
early clinical outcome of moderate–severe community-acquired
pneumonia (CAP)
<4h, n (%) >4h, n (%) OR (95% CI) P-value
Clinical instability 24 (26.4) 22 (36.1) 0.65 (0.32–1.31) 0.22
ICU admission 3 (3.3) 0 (0.0) 2.04 (0.21–20.05)* 0.16
Mortality 1 (1.1) 1 (1.6) 0.65 (0.04–10.68) 0.77
Early clinical failure 27 (29.7) 23 (37.7) 0.69 (0.35–1.35) 0.28
Table 2 The effect of the TFAD
within four hours on early
clinical outcome
*To estimate the odds ratio
mortality in the group, >4 h
is set as 1
Eur J Clin Microbiol Infect Dis (2009) 28:913–919 917would lead to the administration of antibiotics to many
patients in whom the diagnosis of pneumonia is still in
doubt, leading to an increasing rate of inappropriate
antibiotic use, antibiotic resistance, antibiotic-related side-
effects and an decrease in the yield of subsequently
required diagnostic tests [28]. Furthermore, although some
patients may benefit of the early administration of anti-
biotics, there is a risk to other patients who are treated
concurrently and may not receive the same priority as
patients with suspected pneumonia [13, 14].
Some limitations of the current study must be acknowl-
edged. Certainly, the study population is much smaller than
the population included in the large database studies,
although the accuracy of diagnosis in this prospective study
is very high as compared to the coding database studies. As
a valid diagnosis of CAP is crucial for studies on this topic,
it is probably better to rely on the results of several smaller
prospective studies together than on a single large database
study. Owing to the fact that the current study was part of a
therapeutic trial in severe CAP with an intervention on the
third day, results on long-term outcome would probably not
be reliable and are, therefore, not presented. We are aware
that the absence of early deterioration does not necessarily
imply a favourable long-term outcome. However, early
clinical outcome is an appropriate outcome measure for
evaluating therapeutic strategies initiated on admission
[29]. Obviously, a randomised controlled trial is the ideal
study design to investigate the impact of minimising the
TFAD. However, intentionally delaying antibiotic therapy
in pneumonia would be unethical.
Nevertheless, there must be a basis of recommendations
with adequate scientific proof of their evidence, safety and
feasibility to develop performance indicators [16], particu-
larly because the introduction of performance indicators
may have a large impact on clinical practice. Studies
reported that antibiotic administration within four hours in
the emergency department was often not feasible due to
crowding [30]. In our opinion, at this moment, there seems
not to be sufficient evidence in the published literature to
justify the implementation of the TFAD as a performance
indicator and penalise hospitals for not being in compliance
with current guidelines on this behalf. To improve care in
the treatment of pneumonia, it is probably better to focus on
interventions based on established evidence, such as the
correction of hypotension in septic shock or timely oxygen
administration [31, 32]. These interventions seem to be
better targets for performance indicators than minimising
the TFAD. Furthermore, since CAP can be difficult to
diagnose due to the wide variety of clinical symptoms and
differential diagnoses, future research needs to focus on the
development and implementation of adequate diagnostic
algorithms to rapidly discriminate CAP from other clinical
syndromes. A more rapid and reliable diagnosis of CAP
may lead to antibiotics administration early in the course of
disease without increasing unnecessary antibiotic use as
enhanced by the implementation of minimising the TFAD
as a performance indicator.
In conclusion, clinical parameters on admission other
than the TFAD predict early clinical outcome in patients
with moderate–severe CAP admitted to general wards. In
contrast to severe CAP necessitating treatment in the ICU
directly, in the case of suspected moderate–severe CAP, one
can take time to establish a reliable diagnosis before the
administration of antibiotics. Therefore, implementation of
the TFAD as a performance indicator may not be desirable.
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